Challenging the "Undruggable"─Targeting STAT3 but Identifying Potent TrkA-Targeted Inhibitors.

JSON

Iliev P, McCutcheon C, Admas TH, Reithmeier A, Lopez McDonald M, van Outryve A, Hanke D, Brown JI, Haraldsson M, Toillon RA, Frank DA, Page BDG

J. Med. Chem. - (-) - [2025-04-17; online 2025-04-17]

Signal transducer and activator of transcription 3 (STAT3) is a promising yet challenging anticancer drug target due to its complex signaling and limited "druggability". To this end, we herein highlight a target engagement-focused screening and optimization pipeline pursuing the discovery of novel STAT3 inhibitors. From a STAT3 differential scanning fluorimetry high-throughput screen, we identified compounds that appeared to stabilize STAT3 toward thermal aggregation and moderately inhibited cellular STAT3 activity. Subsequent evaluation using complementary and orthogonal assays revealed their high affinity for tropomyosin receptor kinase A (TrkA). Applying a similar target engagement-inspired approach, we refined inhibitor binding and selectivity toward TrkA, showing efficacy in cellular TrkA cancer models. Top compound, PI-15, demonstrated successful target engagement in a cellular thermal shift assay and potently inhibited TrkA activity in cancer cells. These approaches highlight the importance of prioritizing rigorous target engagement validation early in the drug discovery pipeline, resulting in promising new inhibitors.

Chemical Biology Consortium Sweden (CBCS) [Collaborative]

PubMed 40245441

DOI 10.1021/acs.jmedchem.5c00214

Crossref 10.1021/acs.jmedchem.5c00214